Stay updated on Pembrolizumab Neoadjuvant in HCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Neoadjuvant in HCC Clinical Trial page.

Latest updates to the Pembrolizumab Neoadjuvant in HCC Clinical Trial page
- Check4 days agoChange DetectedA new revision tag 'Revision: v3.5.4' was added and the previous tag 'Revision: v3.5.3' was removed, updating the page's revision history.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page’s revision/version number was updated from v3.5.2 to v3.5.3. This indicates a site build or metadata update without changing the underlying study information presented.SummaryDifference0.1%

- Check33 days agoChange DetectedSystem revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check62 days agoChange Detected- Added the disease term 'Hepatocellular carcinoma' and a new resource link to the Genetic and Rare Diseases Information Center. - Updated the site revision from v3.4.3 to v3.5.0.SummaryDifference0.2%

- Check69 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check98 days agoChange DetectedAdded Revision: v3.4.2 and removed the government funding lapse notice and Revision: v3.4.1.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab Neoadjuvant in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Neoadjuvant in HCC Clinical Trial page.